Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

May 7, 2026

Ascendis Pharma Reports First Quarter 2026 Financial Results

May 6, 2026

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

April 30, 2026

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

April 21, 2026

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

April 20, 2026

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

April 8, 2026

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

April 8, 2026

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia

April 6, 2026

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

March 17, 2026

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

March 16, 2026

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© May 2026 Ascendis Pharma